Luminary Learning Gastrointestinal Disorder- Issue 1

Pharmacological and Clinical Treatment of Irritable Bowel Syndrome •  27 31. Matsueda K, Harasawa S, Hongo M, Hiwatashi N et al (2008) A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome. Digestion 77:225–235. 32. Matsueda K, Harasawa S, Hongo M, Hiwatashi N et al (2008) A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 43:1202– 1211. 33. Min YW, Rhee PL (2015) The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D). Therap Adv Gastroenterol 8:136–142. 34. Nee J, Zakari M, Lembo AJ (2015) Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome. Expert Opin Pharmacother 16:2781–2792. 35. Lavo B, Stenstam M, Nielsen AL (1987) Loperamide in treatment of irritable bowel syndrome—A double-blind placebo controlled study. Scand J Gastroenterol Suppl 130:77–80. 36. Karabulut GS, Beser OF, Erginoz E, Kutlu T et al (2013) The incidence of irritable bowel syndrome in children using the Rome III criteria and the effect of trimebutine treatment. J Neurogastroenterol Motil 19:90–93. 37. Delvaux M, Wingate D (1997) Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 25:225–246. 38. FujitaW, Gomes I, Dove LS, Prohaska D et al (2014) Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers. Biochem Pharmacol 92:448–456. 39. Dove LS, Lembo A, Randall CW, Fogel R et al (2013) Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study. Gastroenterology 145:329–338. 40. Lacy BE (2016) Emerging treatments in neurogastroenterology: eluxadoline—A new therapeutic option for diarrhea-predominant IBS. Neurogastroenterol Motil 28:26–35. 41. Laterza L, Ianiro G, Scoleri I, Landi R et al (2015) Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother 16:607–615. 42. Soldi S, Vasileiadis S, Uggeri F, Campanale M et al (2015) Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol 8:309–325. 43. Kane JS, Ford AC (2016) Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 10:431–442. 44. Pimentel M (2016) Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther 43(Suppl 1):37–49. 45. Yeo QM, Crutchley R, Cottreau J, Tucker A et al (2013) Crofelemer, a novel antisecretory agent approved for the treatment of HIV-associated diarrhea. Drugs Today (Barc) 49:239–252. 46. Mangel AW, Chaturvedi P (2008) Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients. Digestion 78:180–186. 47. Chen CH, Lin CL, Kao CH (2016) Irritable bowel syndrome is associated with an increased risk of dementia: a nationwide population-based study. PLoS ONE 11:e0144589. 48. Fichna J, Storr MA (2012) Brain-Gut Interactions in IBS. Front Pharmacol 3:127. 49. Ford AC, Quigley EM, Lacy BE, Lembo AJ et al (2014) Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 109:1350–1365. 50. Vahedi H, Merat S, Momtahen S, Kazzazi AS et al (2008) Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 27:678–684. 51. Awad RA, Camacho S (2010) A randomized, double-blind, placebo-controlled trial of polyethylene glycol effects on fasting and postprandial rectal sensitivity and symptoms in hypersensitive constipation-predominant irritable bowel syndrome. Colorectal Dis 12:1131–1138. 52. Chapman RW, Stanghellini V, Geraint M, Halphen M (2013) Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 108:1508–1515. 53. Tack J, Camilleri M, Chang L, Chey WD et al (2012) Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35:745–767. 54. Brandt LJ (2008)The FDA’s decision-making process: isn’t it time to temper the principle of protective paternalism? Am J Gastroenterol 103:1226–1227. 55. Chey WD, Pare P, Viegas A, Ligozio G et al (2008) Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Am J Gastroenterol 103:1217–1225.